Increased Level of Vascular Endothelial Growth Factors by 4-hexylresorcinol is Mediated by Transforming Growth Factor-β1 and Accelerates Capillary Regeneration in the Burns in Diabetic Animals.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 May 2020
Historique:
received: 22 04 2020
revised: 11 05 2020
accepted: 12 05 2020
entrez: 20 5 2020
pubmed: 20 5 2020
medline: 12 2 2021
Statut: epublish

Résumé

4-Hexyl resorcinol (4HR) is an organic compound and has been used in skin care application. 4HR is an M2-type macrophage activator and elevates vascular endothelial growth factor (VEGF) expression via the hypoxia-inducible factor (HIF)-independent pathway. As endothelial cells are important in wound healing, the human umbilical vein endothelial cells (HUVECs) were treated with 4HR, and changes in VEGF-A, -C, and transforming growth factor-β1 (TGF-β1) expression were investigated. The administration of 4HR increased the expression level of VEGF-A, -C, and TGF-β1. The application of TGF-β1 protein also increased the expression level of VEGF-A and -C. Knockdown with small interfering RNA (siRNA) targeting to TGF-β1 and the selective chemical inhibition (A83-01) to ALK5 confirmed the involvement of the TGF-β signaling pathway in the 4-HR-mediated VEGFs expression. 4HR application in a burn model of diabetic rats demonstrated an increased level of angiogenic proteins with wound healing. Compared to sericin application, the 4HR application group showed more prominent capillary regeneration. Collectively, 4HR activated TGF-β1/ALK5/VEGFs signaling in endothelial cells and induced vascular regeneration and remodeling for wound healing.

Identifiants

pubmed: 32423083
pii: ijms21103473
doi: 10.3390/ijms21103473
pmc: PMC7279008
pii:
doi:

Substances chimiques

RNA, Small Interfering 0
Resorcinols 0
TGFB1 protein, human 0
Transforming Growth Factor beta1 0
VEGFC protein, human 0
Vascular Endothelial Growth Factor A 0
Vascular Endothelial Growth Factor C 0
Receptor, Transforming Growth Factor-beta Type I EC 2.7.11.30
TGFBR1 protein, human EC 2.7.11.30
resorcinol YUL4LO94HK

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Rural Development Administration
ID : PJ01313902

Références

Lancet. 2003 May 3;361(9368):1545-51
pubmed: 12737879
Maxillofac Plast Reconstr Surg. 2020 Mar 5;42(1):5
pubmed: 32206664
Sci Rep. 2019 Mar 4;9(1):3379
pubmed: 30833641
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 1997 Sep;11(5):257-60
pubmed: 9867922
Cancer Sci. 2005 Nov;96(11):791-800
pubmed: 16271073
Burns. 2018 Mar;44(2):386-396
pubmed: 29032969
Clin Sci (Lond). 2004 Dec;107(6):519-32
pubmed: 15324298
Sci Rep. 2019 Mar 5;9(1):3448
pubmed: 30837602
Oncol Rep. 2012 Aug;28(2):677-81
pubmed: 22664654
Maxillofac Plast Reconstr Surg. 2018 Nov 22;40(1):34
pubmed: 30525010
Exp Eye Res. 2017 Nov;164:74-81
pubmed: 28803935
Int J Mol Sci. 2018 Mar 15;19(3):
pubmed: 29543707
J Trauma. 2000 Aug;49(2):327-30
pubmed: 10963547
Endothelium. 2004 Mar-Apr;11(2):89-97
pubmed: 15370068
Arch Dermatol Res. 2013 Aug;305(6):555
pubmed: 23812437
Burns. 2016 Nov;42(7):1534-1541
pubmed: 27198070
Tissue Eng Part A. 2010 May;16(5):1457-68
pubmed: 19938961
Int J Burns Trauma. 2015 Mar 20;5(1):13-21
pubmed: 26064798
Chem Res Toxicol. 2009 Jan;22(1):52-63
pubmed: 19063592
J Am Acad Dermatol. 2014 Jan;70(1):1.e1-18; quiz 19-20
pubmed: 24355275
Cardiovasc Diabetol. 2008 Apr 19;7:8
pubmed: 18423039
Int J Mol Sci. 2017 Jul 03;18(7):
pubmed: 28671607
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Int J Mol Sci. 2020 Feb 24;21(4):
pubmed: 32102282
Skin Res Technol. 2019 Mar;25(2):118-123
pubmed: 30030915
FEBS Lett. 2012 Nov 16;586(22):3951-5
pubmed: 23058288
Biomaterials. 2015 Jan;37:194-207
pubmed: 25453950
Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F167-F180
pubmed: 28978530
Burns. 2016 Dec;42(8):1734-1739
pubmed: 27338180
Maxillofac Plast Reconstr Surg. 2019 Jul 23;41(1):26
pubmed: 31403036

Auteurs

Dae-Won Kim (DW)

Department of Oral Biochemistry, College of Dentistry, Gangneung-Wonju National University, Gangneung 28644, Korea.

You-Young Jo (YY)

Sericultural and Apicultural Division, National Institute of Agricultural Science, Rural Development Administration, Wanju 55365, Korea.

Umberto Garagiola (U)

Biomedical, Surgical and Oral Sciences Department, Maxillofacial and Dental Unit, School of Dentistry, University of Milan, 20122 Milan, Italy.

Je-Yong Choi (JY)

School of Biochemistry and Cell Biology, BK21 Plus KNU Biomedical Convergence Program, Skeletal Diseases Analysis Center, Korea Mouse Phenotyping Center (KMPC), Kyungpook National University, Daegu 41944, Korea.

Yei-Jin Kang (YJ)

Department of Oral and Maxillofacial Surgery, College of Dentistry, Gangneung-Wonju National University, Gangneung 28644, Korea.

Ji-Hyeon Oh (JH)

Department of Oral and Maxillofacial Surgery, College of Dentistry, Gangneung-Wonju National University, Gangneung 28644, Korea.

Seong-Gon Kim (SG)

Department of Oral and Maxillofacial Surgery, College of Dentistry, Gangneung-Wonju National University, Gangneung 28644, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH